Metadata record for the manuscript: Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia

Summary

This
metadata record provides details of the data supporting the claims of the
related manuscript: “Targeting the Epichaperome As an
Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid
Leukemia ”.

The
related study aimed to prospectively identify patients likely to respond to
epichaperome inhibitors to measure target engagement and dependency during
treatment by developing a flow cytometry-based assay for evaluation and
monitoring of epichaperome abundance at the single-cell level.

Subject of
data: leukaemia cells from a patient with an unclassified myeloproliferative
neoplasm harbouring a novel PML-SYK fusion that transformed to AML

Sample size:
case report containing data from a single patient

Data
access

All
data are shared openly. The RNA sequencing and whole exome sequencing data are
shared in the European Genotype-phenotype
Archive under accession https://identifiers.org/ega.study:EGAS00001004992. All other data are shared as part of this figshare
metadata record. A list of which datafiles underlie which figures in the
manuscript is also included in Excel .xlsx format in the file ‘sugita_datafiles_underlying_figures_lookup.xlsx’.

Corresponding authors

Monica L.
Guzman, Ph.D., Weill Cornell Medicine, 1300 York Ave, C-610C, Box 113, New
York, NY 10065. Email: [e-mail]

Juan Miguel
Mosquera, M.D, M.Sc., Weill Cornell Medicine, 1300 York Ave, Box 69, New York,
NY 10065. Email: [e-mail]

Name of Institutional Review Board or ethics
committee that approved the study

All experimental procedures
were carried out in accordance with approved guidelines and were approved by
the Institutional Review Board (IRB) at Weill Cornell Medicine. Patients in the
study signed informed written consent under an IRB-approved protocol (IRB #1305013903).